Bill C-17 amends the Food and Drugs Act, which hasn’t been substantially updated in over 50 years. It was introduced to the House of Commons by the Minister of Health in December 2013. The Bill has two main goals:
- Strengthen safety oversight of therapeutic products throughout their lifecycle
- Improve reporting of serious adverse reactions and incidents.
The Bill applies to: prescription and OTC drugs, vaccines, gene therapies, cells, tissues and organs, and medical devices. The Bill does not apply to natural health products.